Súčasné možnosti a pohľad na liečbu kastračne refraktérneho metastatického karcinómu prostaty // SOLEN

Onkológia 5/2019

Current possibilities and view of treatment of castration refractory metastatic prostate cancer

Prostate cancer is currently known as the most common cancer and the second leading cause of death from cancer in men in Western population. Advanced prostate cancer is initially sensitive to androgen-deprivation therapy (ADT) but later on progresses to castrationresistant state. Understanding the mechanisms that transform prostate cancer (PCA) into a castration-resistant state enables investigators to explore supression of extraresticular andronegs and other critical pathways to suggest appropriate and rational therapeutic design. We have new ARTA drugs at our disposal, in patients previously treated with chemotherapy as well as for chemonaive. Chemotherapy still plays important role in selected patients. In some others specific imunnotherapy appears to be effective. Some targeted drugs also have demonstrated promising activity.

Keywords: prostate cancer, androgen-deprivation therapy, castrate resistant, immunotherapy, check point inhibitors